Pay in 4 interest-free payments of $5.48 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
The starting dose period, with its minimal weight loss, carries very low risk
Strong outcomes there would strengthen the case for approval and help define who benefits most
Wegovy requires in-person or telehealth visits through specific provider networks, which may limit scheduling flexibility
Neither appears to offer significant advantages over the other
Key Takeaway: Tirzepatide targets two metabolic receptors (GLP-1/GIP) to offer up to 20.9% average weight loss, while Retatrutide attacks fat storage via three pathways (GLP-1/GIP/Glucagon), yielding unprecedented weight loss averages near 24.2% in Phase 2 trials
US$ 22.79
US$ 26.81
US$ 28.52
US$ 24.27
